UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 167

Sortiert nach

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry

World journal of gastroenterology : WJG, 2006-03, Vol.12 (10), p.1536

2006

Volltextzugriff (PDF)

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

Marine drugs, 2018-07, Vol.16 (7), p.246

2018

Volltextzugriff (PDF)

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Clinical cancer research, 2017-08, Vol.23 (16), p.4540-4544

2017

Volltextzugriff (PDF)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

The New England journal of medicine, 2019-10, Vol.381 (17), p.1632-1643

2019

Volltextzugriff (PDF)

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Clinical pharmacokinetics, 2010-08, Vol.49 (8), p.493-507

2010

Volltextzugriff (PDF)

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

The New England journal of medicine, 2009-07, Vol.361 (2), p.123-134

2009

Volltextzugriff (PDF)

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Journal of clinical oncology, 2019-06, Vol.37 (17), p.1460-1469

2019

Volltextzugriff (PDF)

Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010-03, Vol.878 (7), p.621-627

2010

Volltextzugriff (PDF)

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

European journal of cancer (1990), 2017-05, Vol.76, p.144-151

2017

Volltextzugriff (PDF)

Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers

Cell death and differentiation, 2019-11, Vol.26 (11), p.2223-2236

2019

Volltextzugriff (PDF)

Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review

Anti-cancer drugs, 2014-06, Vol.25 Update on Taxanes in Cancer Therapy (5), p.488-494

2014

Volltextzugriff (PDF)

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time

European journal of cancer (1990), 2016-02, Vol.54, p.40-48

2016

Volltextzugriff (PDF)

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Computer methods and programs in biomedicine, 2011, Vol.101 (1), p.72-79

2011

Volltextzugriff (PDF)

Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD2A variant: A matched pair analysis

International journal of cancer, 2019-05, Vol.144 (9), p.2347-2354

2019

Volltextzugriff (PDF)

Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients

BMC cancer, 2008-12, Vol.8 (1), p.389-389, Article 389

2008

Volltextzugriff (PDF)

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Clinical cancer research, 2011-05, Vol.17 (10), p.3455-3468

2011

Volltextzugriff (PDF)

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

Trends in pharmacological sciences (Regular ed.), 2006, Vol.27 (1), p.17-24

2006

Volltextzugriff (PDF)

P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel

International journal of cancer, 2013-05, Vol.132 (10), p.2439-2447

2013

Volltextzugriff (PDF)

Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score

Pharmacogenomics, 2015-07, Vol.16 (11), p.1277-1284

2015

Volltextzugriff (PDF)

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec) : Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients

Cancer research (Chicago, Ill.), 2005-04, Vol.65 (7), p.2577-2582

2005

Volltextzugriff (PDF)

High-Tech Drugs in Creaky Formulations

Pharmaceutical research, 2017-09, Vol.34 (9), p.1751-1753

2017

Volltextzugriff (PDF)

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care

European journal of cancer (1990), 2016-02, Vol.54, p.120-130

2016

Volltextzugriff (PDF)

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis

Antimicrobial agents and chemotherapy, 2015-01, Vol.59 (1), p.1-14

2015

Volltextzugriff (PDF)

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

Anti-cancer drugs, 2001-04, Vol.12 (4), p.315-323

2001

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(163)
Mit Volltextzugriff
(153)

Publikationsform

Artikel
(167)

Sprache

Englisch
(167)
Japanisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry

Review of Chromatographic Bioanalytical Assays for the Quantitative Determination of Marine-Derived Drugs for Cancer Treatment

Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours

Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers

Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time

Piraña and PCluster: A modeling environment and cluster infrastructure for NONMEM

Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD2A variant: A matched pair analysis

Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients

Relationship between Single Nucleotide Polymorphisms and Haplotypes in DPYD and Toxicity and Efficacy of Capecitabine in Advanced Colorectal Cancer

Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs

P‐glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel

Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec) : Implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients

High-Tech Drugs in Creaky Formulations

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care

Systematic review of biomarkers to monitor therapeutic response in leishmaniasis

Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers

Suchergebnisse filtern